Evidence map›Paper›PMID 38953893›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2024

Evaluation of the Immune Response within the Tumor Microenvironment in African American and Non-Hispanic White Patients with Non-Small Cell Lung Cancer.

Matthew R Trendowski, Donovan Watza, Christine M Lusk, Fulvio Lonardo, Valerie Ratliff, Angela S Wenzlaff, Hirva Mamdani, Christine Neslund-Dudas, Julie L Boerner, Ann G Schwartz and 1 more

Abstract read
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Matthew R TrendowskiDepartment of Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan.ORCID 0000-0001-7006-7065
Donovan WatzaDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Washington University School of Medicine in St. Louis, St. Louis, Missouri.ORCID 0000-0002-6882-065X
Christine M LuskDepartment of Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan.ORCID 0000-0001-8915-4628
Fulvio LonardoDepartment of Pathology, Wayne State University School of Medicine, Detroit, Michigan.ORCID 0000-0002-5728-9082
Valerie RatliffDepartment of Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan.ORCID 0009-0002-8201-6796
Angela S WenzlaffDepartment of Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan.ORCID 0000-0001-8669-8240
Hirva MamdaniDepartment of Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan.ORCID 0000-0003-3874-8703
Christine Neslund-DudasDepartment of Public Health Sciences, Henry Ford Health, Detroit, Michigan.ORCID 0000-0002-2506-1964
Julie L BoernerDepartment of Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan.ORCID 0000-0003-1711-4998
Ann G SchwartzDepartment of Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan.ORCID 0000-0002-9525-1157
Heather M GibsonDepartment of Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan.ORCID 0000-0003-2652-8252

Funding

Tumor Biology and Microenvironment (Program 1)P30CA022453 · NCI · WAYNE STATE UNIVERSITY · PI PAUL M STEMMER · 1985 to 2026
$68.4M
The impact of the COVID-19 pandemic on African American cancer survivors and their caregiversU01CA199240 · NCI · WAYNE STATE UNIVERSITY · PI Jennifer L Beebe-Dimmer, Ann G. Schwartz · 2017 to 2026
$15.2M
Inflammation Pathways and COPD in the Development of Lung CancerR01CA141769 · NCI · WAYNE STATE UNIVERSITY · PI SCHWARTZ, ANN G. · 2011 to 2016
$8.7M
TRAINING PROGRAM IN THE BIOLOGY OF CANCERT32CA009531 · NCI · WAYNE STATE UNIVERSITY · PI Larry H Matherly · 1985 to 2026
$5.3M
Reducing Cancer Health Disparities in DetroitP20CA262735 · NCI · WAYNE STATE UNIVERSITY · PI SCHWARTZ, ANN G. · 2021 to 2023
$3.0M
Herrick FoundationNational Cancer Institute (NCI) P20CA262735National Cancer Institute (NCI) R01CA141769National Institutes of Health (NIH) T32-CA009531NCI NIH HHS P20 CA262735NCI NIH HHS P30 CA022453NCI NIH HHS R01 CA141769NCI NIH HHS T32 CA009531NCI NIH HHS U01 CA199240
6 · The paper itself

Abstract

backgroundAfrican Americans have higher incidence and mortality from lung cancer than non-Hispanic Whites, but investigations into differences in immune response have been minimal. Therefore, we compared components of the tumor microenvironment among African Americans and non-Hispanic Whites diagnosed with non-small cell lung cancer based on PDL1 or tertiary lymphoid structure (TLS) status to identify differences of translational relevance.

methodsUsing a cohort of 280 patients with non-small cell lung cancer from the Inflammation, Health, Ancestry, and Lung Epidemiology study (non-Hispanic White: n = 155; African American: n = 125), we evaluated PDL1 tumor proportion score (<1% vs. ≥1%) and TLS status (presence/absence), comparing differences within the tumor microenvironment based on immune cell distribution and differential expression of genes.

resultsTumors from African Americans had a higher proportion of plasma cell signatures within the tumor microenvironment than non-Hispanic Whites. In addition, gene expression patterns in African American PDL1-positive samples suggest that these tumors contained greater numbers of γδ T cells and resting dendritic cells, along with fewer CD8+ T cells after adjusting for age, sex, pack-years, stage, and histology. Investigation of differential expression of B cell/plasma cell-related genes between the two patient populations revealed that two immunoglobulin genes (IGKV2-29 and IGLL5) were associated with decreased mortality risk in African Americans.

conclusionsIn the first known race-stratified analysis of tumor microenvironment components in lung cancer based on PDL1 expression or TLS status, differences within the immune cell composition and transcriptomic signature were identified that may have therapeutic implications. IMPACT: Future investigation of racial variation within the tumor microenvironment may help direct the use of immunotherapy.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsTumor MicroenvironmentAgedB7-H1 AntigenBlack or African AmericanFemaleHumansMaleMiddle AgedWhiteB7-H1 AntigenCD274 protein, human

Identifiers

PMID38953893
PMCPMC11371519

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.